PLSHOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
PANACEA LIFE SCIENCES HOLDINGS, INC.
Financials through Q1 FY2024, quarter ended Mar 31, 2024Last filing: 10-Q on May 6, 2024
$0.07+0.00 (+5.45%)
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2023
Gross margin
47.0%
Operating margin
-232.5%
Net margin
-336.1%
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +46.6% | -35.8% | – | – | |
| Gross profit | +183.0% | -17.5% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Return on equity | -247.7% | 153.8% | 153.6% | |
| Return on assets | – | -4639.8% | -42.8% | |
| Current ratio | 1.47 | 0.00 | 0.24 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | -5.2× | -3.6× | |
| Inventory turnover | – | – | 0.3× | |
| Capex to revenue | 706.3% | – | 2.7% | |
| Diluted shares | 0M | 0M | 17M |
Where the cash went
Fiscal 2019 to 2023, five years combined
Panacea Life Sciences generated $21.24M from operations and spent $4.21M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$21.24M
Used
$4.21M
Capital expenditure$4.21M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-336.1%
×Asset turnover0.13×
×Equity multiplier-3.59×
=Return on equity, FY2023153.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -336.1% | 0.13× | -3.59× | 153.6% |
| FY2022 | -561.9% | 0.08× | 8.73× | -368.8% |
| FY2021 | -232.2% | 0.07× | 3.99× | -69.3% |
| FY2020 | -58.0% | 0.46× | 2.11× | -56.1% |
| FY2019 | -2898.3% | 0.09× | 0.94× | -235.3% |
| FY2015 | -168064.3% | 0.00× | -3.57× | 1505.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
3of 8 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.02M
- Cash generatingOperating cash flow above zero-$1.52M
- Return on assets improvedROA up on the prior year-38.4% → -41.1%
- Earnings backed by cashOperating cash flow above net income-$1.52M vs -$8.02M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.42 → 0.24
- No dilutionShare count did not rise15M → 17M
- Gross margin improvedGross margin up on the prior year24.37% → 47.04%
- More efficientAsset turnover rose0.07 → 0.12